# Age at Menarche and Coronary Artery Disease Risk: Divergent Associations with Different Sources of Variation

Ambreen Sonawalla, MD,[a,b] Daniel I. Chasman, PhD,[b,c] Yee-Ming Chan, MD, PhD[a,b].
[a]Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, [b]Departments of Pediatrics (A.S., Y.M.C.) and Medicine (D.I.C.), Harvard Medical School, [c]Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital

**Short title:** Age at Menarche and Coronary Artery Disease

**Address for correspondence:** Ambreen Sonawalla, MD; ambreen.sonawalla@childrens.harvard.edu; 300 Longwood Avenue, Boston, MA 02115. Phone: 617-355-0796, fax: 617-730-0194. ORCID: 0000-0003-4342-5343

**Email addresses:**

Yee-Ming Chan: yee-ming.chan@childrens.harvard.edu; Daniel I. Chasman: dchasman@bwh.harvard.edu

DISCLOSURE SUMMARY

A.S. has no relevant disclosures or relationships with industry. D.I.C has no relevant disclosures or relationships with industry. Y.-M.C. receives royalties from UpToDate on topics related to puberty.

**Abstract**

**Background:** In women, both earlier and later age at menarche (AAM) are associated with increased risk of coronary artery disease (CAD). This study sought to determine if the relationship of AAM with CAD and CAD risk factors differs for different underlying sources of variation in AAM – specifically, variation attributable to common genetic variants as represented by a polygenic score (PGS) vs. variation in AAM adjusted for the PGS.

**Methods:** Primary analyses were conducted on data from 201,037 women in the UK Biobank and validation studies on data from 23,268 women in the Women's Genome Health Study (WGHS). For each individual, a PGS for AAM was calculated, then two variables were estimated from linear regression models: the genetically predicted AAM (the estimated AAM for each woman solely due to the effects of common genetic variants) and the PGS-adjusted AAM (estimated AAM for each woman solely due to factors other than the PGS). Logistic regression and linear splines were then used to study the relationships of these variables with CAD and CAD risk factors.

**Results:** Genetically predicted AAM demonstrated a linear relationship with CAD and linear or roughly linear relationships with CAD risk factors. In contrast, PGS-adjusted AAM demonstrated a U-shaped relationship with CAD and with hemoglobin A1c, triglycerides, HDL-C, and waist-hip ratio. Validation studies using WGHS data produced similar results.

**Conclusions:** These results suggest that later AAM itself does not cause increased risk of CAD; rather, upstream sources of variation other than common genetic variants can cause both later AAM and increased risk of CAD. Dysglycemia, dyslipidemia, and central adiposity are candidate mediators of the association of later AAM with increased risk of CAD.

Key words: pubertal timing, polygenic score, women, UK Biobank.

Non-standard Abbreviations and Acronyms:

AAM: age at menarche

BMI: body-mass index

CAD: coronary artery disease

DBP: diastolic blood pressure

HbA1c: hemoglobin A1c

HDL-C: high-density lipoprotein cholesterol

LDL-C: low-density lipoprotein cholesterol

PGS: polygenic score

SBP: systolic blood pressure

WGHS: Women's Genome Health Study

## INTRODUCTION

Many pathologies manifesting in adulthood have antecedents in childhood. There is growing evidence that coronary artery disease (CAD) in women, a leading cause of morbidity and mortality in the world, is associated with both earlier and later age at menarche (AAM), a hallmark of pubertal timing (1–4). *Earlier* puberty is associated with increased risk of CAD in both men and women; however, the association between *later* puberty and increased risk of CAD appears to be unique to women; in men, later puberty is associated with a decreased risk of CAD (3). A deeper exploration of these childhood antecedents would allow a better understanding of the pathogenesis of CAD in adulthood, specifically identify factors that uniquely affect women and facilitate the development of targeted preventive interventions, potentially as early as childhood.

Multiple studies have associated earlier AAM with a higher risk of developing components of the metabolic syndrome, namely obesity, type 2 diabetes mellitus, hypertension, and dyslipidemia (3,5–9). Studies have further suggested that the association between earlier AAM and risk of CAD is mediated by adiposity (10,11). In contrast, the associations of later AAM reported to date do not fit neatly into the paradigm of metabolic syndrome. Later AAM is associated with lower rather than higher body-mass index (BMI) (3,12,13), and studies on other components of the metabolic syndrome have produced conflicting results, with some studies showing association of later AAM with higher risk of hypertension (1,14), others showing a lower risk of hypertension (3) or type 2 diabetes (15), and yet others showing no association with hypertension, type 2 diabetes, or hypercholesterolemia (3,16). Hence, while earlier AAM has

been associated with several CAD risk factors, there may be distinct mechanisms underlying the association of later AAM with increased risk of CAD.

Variation in AAM can stem from several upstream sources, including genetics (both common genetic variants and rare genetic variants), acquired factors such as chronic illness, chronic stress, underweight, and undernutrition, and environmental factors such as family composition (e.g., presence or absence of father) (17). It is possible that some of these sources of variation may influence risk of CAD only through their influence on AAM, while others may directly influence CAD risk and features of the metabolic syndrome (Figure 1). Thus, dissecting variation in AAM based on underlying sources of variation could provide a clearer understanding of the relationship of AAM with CAD.

Genetics is a major source of variation in AAM, with half to three-quarters of variation attributable to genetics (18,19). A 2017 genome-wide association study (GWAS) on AAM identified 389 independent single-nucleotide polymorphisms (SNPs) associated with AAM at genome-wide significance (20). The results from this GWAS allow the calculation of a polygenic score (PGS) for a given individual to reflect the cumulative contribution of common genetic variants to AAM.

Previous studies have used PGSs to dissect the influence of genetics vs. environmental factors (or other factors not captured by the PGS) that contribute to traits such as BMI and LDL-C (21,22). These studies have found that associations of these traits with health outcomes differ

between genetically and environmentally influenced traits. For example, obesity driven by environmental factors was associated with more harmful cardiovascular outcomes than genetically predicted obesity (21), suggesting that dissecting effects based on underlying source of variation can allow deeper insights into pathogenic mechanisms.

The aims of this study were two-fold: first, to determine if the association between later AAM and increased risk of CAD depends on the underlying source of variation in AAM – specifically, common genetic variation vs. other sources of variation; second, to study the relationships of these different sources of variation in AAM with CAD risk factors.

## METHODS

To study how different sources of variation in the timing of menarche are associated with risk of CAD, two variables were calculated: genetically predicted AAM (the estimated AAM determined solely by the effects of common genetic influences, as estimated by a PGS for AAM) and PGS-adjusted AAM (the estimated AAM determined solely by factors other than common genetic variants, the PGS).

### *Study cohorts*

This study used data from two cohorts: the UK Biobank for primary analyses and the Women's Genome Health Study (WGHS) for validation analyses. The UK Biobank is a population-based cohort of over 500,000 men and women in the UK 40 years and older at the time of recruitment,

127 with extensive health-related phenotypic and laboratory data as well as individual-level genetic
128 data (23). This study analyzed data from 201,037 unrelated women in the UK Biobank of non-
129 Finnish European ancestry (as determined through principal component analysis) (24) who had
130 genetic and self-reported AAM data. During data collection in the UK Biobank, any value of
131 AAM <5 years or >25 years was rejected, and any AAM entered as <6 years or >20 years
132 required confirmation from participants (25). Women with missing AAM data were excluded
133 from analysis. The UK Biobank obtained the multiple ethical and regulatory approvals required
134 for recruitment and research procedures, and participants provided written consent (23). The
135 WGHS is a cohort of initially healthy American women aged 45 years and older at enrollment
136 with genetic and phenotypic data, followed over 26-28 years for cardiovascular and other
137 outcomes (26). This analysis studied data from 23,268 women in the WGHS who had genetic
138 and self-reported AAM data. Self-reported AAM ≤9 years or ≥ 17 years were entered as 9 years
139 or 17 years, respectively. The WGHS was approved by the institutional review board of Brigham
140 and Women's Hospital, and participants consented to ongoing analyses (26).

141

142 *Polygenic score calculation*

143 A PGS was calculated for each woman in the above cohorts in two steps. The first step used the
144 PRS-CS algorithm, which allows the inclusion of all available SNPs from the GWAS on AAM
145 (20), not just those that meet a given *p*-value threshold, and weights the SNP effect sizes based
146 on their significance and adjusts for linkage disequilibrium (27). The use of this algorithm has
147 the potential to explain more variability in AAM than algorithms that use only the SNPs that
148 meet a given significance threshold. The second step calculated the PGS using PRSice-2
149 (without clumping or thresholding) to sum the weighted effect sizes for all SNPs in each

150 individual with the ability to incorporate the probabilistic genotype dosages generated by
151 imputation (28).

152

153 *Subdividing variation in age at menarche*

154 Using each full cohort, regression of self-reported AAM was performed against the PGS for
155 AAM, with the first 10 genetic principal components, assessment center and technical variables
156 such as array number as covariates. The following two variables were then calculated for each
157 individual:

158 1. Genetically predicted AAM: This represents the estimated AAM that each woman would
159 have had if her AAM were determined solely by her common genetic variants, as
160 estimated by the PGS. Statistically, it is the AAM predicted by the regression of AAM
161 against the PGS (Supplemental Figure 1, (29)).
162 2. PGS-adjusted AAM: This represents the estimated AAM that each woman would have
163 had if there were no effect of her common genetic variants (as represented by the PGS),
164 i.e., her AAM were determined solely by sources of variation other than common genetic
165 variants. Statistically, this was the residual of the regression of AAM against the PGS for
166 each individual, added to the AAM corresponding to the mean PGS (to simulate a
167 scenario in which the contribution of the PGS is the same for all women) (Supplemental
168 Figure 1, (29)).

169

170 *Outcomes and analytical methods*

171 The study's primary outcome variable was CAD risk. In the UK Biobank, prevalent CAD at
172 baseline was determined as previously described using a combination of self-report, ICD-9/10
173 codes, and procedure codes (24). The WGHS recruited middle-aged female healthcare
174 professionals with no history of CAD at baseline and identified validated incident CAD during
175 26-28 years of follow-up as described previously (26). Secondary outcome variables were CAD
176 risk factors at baseline for both cohorts: hemoglobin A1c (HbA1c), triglycerides, high-density
177 lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), systolic blood
178 pressure (SBP), diastolic blood pressure (DBP), and BMI; data on waist-hip ratio was available
179 at baseline in the UK Biobank and 6 years after recruitment in the WGHS.

180

181 The relationship of genetically predicted AAM and PGS-adjusted AAM was studied with logistic
182 regression for prevalent CAD, with Cox proportional hazards models for incident CAD, and with
183 linear splines for each continuous variable (HbA1c, triglycerides, HDL-C, LDL-C, SBP, DBP,
184 BMI, waist-hip ratio), with a knot at 12.94 years, which is the AAM corresponding to the mean
185 PGS. Because we observed nonlinear relationships, we also used linear splines to separately
186 analyze values of genetically predicted and PGS-adjusted AAM earlier and later than the mean.
187 For analyses with LDL-C, results were corrected for self-reported use of cholesterol-lowering
188 medications – these were specific LDL-lowering medications in the UK Biobank, (statins,
189 ezetimibe, and bile-acid sequestrants) and collective cholesterol-lowering medications in the
190 WGHS; additional analyses included only women not taking these medications.

191 Covariates of age and age$^2$ were used for all analyses. Analyses were conducted using R v.4.3.1.
192 A significance threshold of 0.05 was used.

To determine if results in the UK Biobank were biased by overfitting as a result of the UK Biobank having contributed to the GWAS for AAM, analyses of CAD were repeated using a PGS calculated using an earlier GWAS that did not include the UK Biobank (30). Furthermore, to determine if outlier values of AAM were disproportionately affecting results, analyses were repeated after excluding women with extreme values of AAM such that up to 0.1% of women were excluded at each extreme.

## RESULTS

To understand potential different effects of different sources of variation in AAM, we constructed two hypothetical scenarios. In the first scenario, a woman's AAM is determined solely by the effects of common genetic variants. We refer to the estimated AAM in this scenario as "genetically predicted AAM." In the second scenario, a woman's AAM is determined solely by the effects of factors other than common genetic variants (or more precisely, by factors other than the PGS). We refer to the estimated AAM in this scenario as "PGS-adjusted AAM."

To examine the differential associations of these two sources of variation with CAD risk, we analyzed data from 201,037 unrelated, non-Finnish European women in the UK Biobank. We first calculated a PGS for AAM for each woman, then regressed self-reported AAM against the PGS for AAM to calculate genetically predicted AAM and to derive PGS-adjusted AAM (Supplemental Figure 1, (29)). For instance, for an individual with a self-reported AAM of 16 years and a PGS of 0.357, the regression provided a genetically predicted AAM of 13.42 years

215 and a residual of 2.58 years. In the regression, the AAM corresponding to the mean PGS was
216 12.95 years, and hence the PGS-adjusted AAM was 2.58 + 12.95 = 15.53 years.

217

218 For women in the UK Biobank, the regression of self-reported AAM against the PGS for AAM
219 demonstrated that the PGS accounted for 15.8% of the variation in AAM. Genetically predicted
220 AAM had a mean ± standard deviation of 12.95 ± 0.64 years, and PGS-adjusted AAM had a
221 mean ± standard deviation of 12.94 ± 1.47 years with a standard deviation of 1.47 years
222 (Supplemental Figure 2, (29)). We then studied the associations of genetically predicted AAM
223 and PGS-adjusted AAM with risk of CAD and with CAD risk factors.

224

225 *Risk of coronary artery disease*

226 Risk of CAD demonstrated a linear relationship with genetically predicted AAM but a non-
227 linear, U-shaped relationship with PGS-adjusted AAM (Figure 2). In the linear relationship of
228 genetically predicted AAM with risk of CAD; each 1-year increase in genetically predicted
229 AAM was associated with an odds ratio (OR) for CAD of 0.91. In other words, for every 1 year
230 that AAM was later due solely to the effects of common genetic variants (as estimated by the
231 PGS), the odds of CAD were lower by 9% (Table 1). To assess for non-linear relationships,
232 linear spline analyses were done which showed no difference in slopes when genetically
233 predicted AAM was earlier vs. later than the mean (Table 1). This lack of difference in slopes
234 indicates that the linear relationship of genetically predicted AAM and risk of CAD extends
235 across all values of genetically predicted AAM.

236

237 In contrast, the association between PGS-adjusted AAM and risk of CAD was U-shaped, with
238 both earlier and later values associated with increased CAD risk (Figure 2). For PGS-adjusted
239 AAM that was earlier than the mean, each 1-year increase (causing AAM to be less early) was
240 associated with an OR for CAD of 0.91 (Table 1). In other words, in women whose PGS-
241 adjusted AAM was earlier than the mean, for every 1 year that AAM was less early due to
242 factors other than the PGS, the odds of CAD were lower by 9%. In contrast, for PGS-adjusted
243 AAM later than the mean, each 1-year increase (causing AAM to be even later) was associated
244 with an OR for CAD of 1.11, i.e., the odds of CAD were higher by 11% (Table 1).

245

246 Because the 2017 AAM GWAS meta-analysis included data from the UK Biobank, which could
247 introduce bias in the above analyses, we conducted sensitivity analyses using the results from an
248 AAM GWAS meta-analysis published in 2014 that did not include the UK Biobank. These
249 analyses showed similar results for CAD (Supplemental Figure 3, Supplemental Table 1, (29)).
250 We also conducted sensitivity analyses excluding women with extreme values of AAM (at the
251 upper and lower 0.1%) and obtained similar results.

252

253 *Hemoglobin A1c*

254 We then examined the associations of genetically predicted AAM and PGS-adjusted AAM with
255 CAD risk factors. Just as the relationship between genetically predicted AAM and CAD was
256 linear, we observed linear (or roughly linear) relationships between genetically predicted AAM
257 and most CAD risk factors. In contrast, for PGS-adjusted AAM we observed mostly non-linear
258 relationships with CAD risk factors.

For hemoglobin A1c, an indicator of average blood glucose over the preceding 3 months, genetically predicted AAM demonstrated a roughly negative linear relationship, with later genetically predicted AAM associated with lower HbA1c (Figure 3). Linear spline analyses indicated that while both slopes were negative, for values of genetically predicted AAM earlier than the mean, the slope of the association with HbA1c was slightly steeper than for values of genetically predicted AAM later than the mean (-0.034 and -0.022 %/year, respectively; *p* for difference between slopes: $7 \times 10^{-5}$; Table 1). In contrast, PGS-adjusted AAM demonstrated a U-shaped relationship with HbA1c: both earlier and later PGS-adjusted AAM were associated with an increase in HbA1c (for values earlier than the mean: slope = -0.022 %/year, for values later than the mean: slope = 0.007%/year; *p* for difference between slopes $< 2 \times 10^{-16}$; Figure 3, Table 1). This was similar to the U-shaped relationship of PGS-adjusted AAM with CAD risk.

Comparing genetically predicted AAM and PGS-adjusted AAM, for values earlier than the mean, the slopes for the associations with HbA1c were comparable (Table 1). However, for values of AAM later than the mean, different slopes were seen for genetically predicted vs. PGS-adjusted AAM; as noted above, for every 1 year that AAM was delayed, HbA1c *decreased* by 0.01% for genetically predicted AAM but *increased* by 0.007% for PGS-adjusted AAM.

*Lipids*

Genetically predicted AAM demonstrated linear relationships with triglycerides and HDL-C (Figure 3), with later genetically predicted AAM associated with lower triglycerides and higher

281 HDL-C (Figure 3) and no significant difference in slopes between earlier and later genetically
282 predicted AAM (*p* for difference in slopes for triglycerides = 0.83 mg/dL/year, for HDL-C =
283 0.38 mg/dL/year; Table 1). In contrast, PGS-adjusted AAM demonstrated non-linear
284 relationships with HDL-C and triglycerides – U-shaped for triglycerides and inverted-U-shaped
285 for HDL-C (Figure 3) - with both increasingly earlier and later PGS-adjusted AAM associated
286 with higher triglycerides and lower HDL-C (Figure 3, Table 1).
287
288 For LDL-C, associations showed a less clear pattern. Earlier genetically predicted AAM showed
289 no association with LDL-C, and later genetically predicted AAM showed a negative linear
290 relationship (Table 1). In contrast, for PGS-adjusted AAM, earlier values showed a negative
291 linear relationship, but later PGS-adjusted AAM showed no significant association (Figure 3,
292 Table 1). Similar results were seen when analyses excluded those taking LDL-lowering
293 medications (Table 1).
294
295 *Blood pressure*
296 Later genetically predicted AAM was associated with both lower SBP and lower DBP (Figure
297 3), with no significant difference between the slopes for values of genetically predicted AAM
298 earlier vs. later than the mean (Table 1). Later PGS-adjusted AAM was also associated with
299 lower SBP and DBP (Figure 3), but the slopes of the associations were steeper for values of
300 PGS-adjusted AAM that were earlier vs. later than the mean (Table 1).
301
302 *Adiposity*

303 We studied two estimates of adiposity: BMI and waist-hip ratio. For BMI, we found a roughly
304 negative linear relationship between genetically predicted AAM and BMI, with later genetically
305 predicted AAM associated with lower BMI (Figure 3, Table 1). The slope of the association with
306 BMI was slightly steeper for values of genetically predicted AAM earlier vs. later than the mean
307 (Table 1). This pattern was similar to the relationship seen between genetically predicted AAM
308 and HbA1c.

309

310 For PGS-adjusted AAM, a different relationship was seen with BMI (Figure 3). While later PGS-
311 adjusted AAM was consistently associated with lower BMI, the slope of the association was ten-
312 fold steeper for values earlier vs. later than the mean (-0.80 kg/m2/year vs. -0.079 kg/m2/year
313 respectively; *p* for difference between slopes $2 \times 10^{-16}$; Table 1). This resembled the patterns seen
314 with SBP and DBP.

315

316 For waist-hip ratio, genetically predicted AAM showed a negative linear association, with no
317 significant difference in slopes for the association when genetically predicted AAM was earlier
318 vs. later than the mean (Figure 3, Table 1). In contrast, the relationship of PGS-adjusted AAM
319 with waist-hip ratio was U-shaped, with values both earlier and later than the mean associated
320 with higher waist-hip ratio (Figure 3, Table 1), similar to the associations seen with CAD,
321 HbA1c, triglycerides, and HDL-C.

322

323 *Validation in the Women's Genome Health Study*

Validation studies using data from the WGHS produced results similar to the above results for the UK Biobank. In the WGHS, genetically predicted AAM showed linear relationships with HbA1c, triglycerides, HDL-C, SBP, DBP, BMI and waist-hip ratio and no clear relationship with LDL-C (Figure 4). Just as in the UK Biobank, PGS-adjusted AAM showed U-shaped relationships with triglycerides and HbA1c, an inverted-U-shaped relationship with HDL-C, and a not completely linear relationship with BMI in the WGHS (Figure 4).

There were two differences between results from the WGHS and the UK Biobank: 1) for SBP and DBP, PGS-adjusted AAM showed roughly U-shaped relationships in the WGHS (Figure 4) rather than the not fully linear relationships seen in the UK Biobank (Figure 3), and 2) for waist-hip ratio, PGS-adjusted AAM showed a negative linear relationship for values earlier than the mean but no significant relationship for values later than the mean in the WGHS (Figure 4) compared to the clear U-shaped relationship seen in the UK Biobank (Figure 2).

For risk of CAD itself, the relationship of genetically predicted AAM with CAD in the WGHS was similar to that in the UK Biobank (Figure 5, Supplemental Table 1, (29)), with a negative linear relationship in both cohorts. For the relationship of PGS-adjusted AAM with CAD, analyses in the WGHS demonstrated a reverse-J shaped relationship (Figure 5, Supplemental Table 1, (29)), slightly different from the U-shaped relationship seen in the UK Biobank.

## DISCUSSION

345 In this study, we dissected variation in AAM into variation attributable to common genetic
346 variants, as estimated by a PGS, (as reflected by genetically predicted AAM), and variation
347 adjusted for the PGS (as reflected by PGS-adjusted AAM), and we found different relationships
348 with these two sources of variation in AAM with risk of CAD and with CAD risk factors,
349 particularly when causing AAM to occur later.

350

351 In general, later AAM showed favorable associations when attributable to common genetic
352 variation (as estimated by the PGS) and harmful or neutral associations when attributable to
353 other yet-to-be-identified sources of variation. If all sources of variation were affecting CAD and
354 CAD risk factors wholly through AAM itself, the associations would be similar regardless of the
355 source of variation studied. Our finding that these associations varied based on the underlying
356 source of variation driving later AAM therefore indicates that it is not later AAM itself that
357 causes increased risk of CAD. Rather, there appear to be PGS-independent factors that cause
358 both later AAM and increased risk of CAD and unfavorable cardiometabolic risk profiles. Such
359 factors could include environmental or acquired influences (such as chronic illnesses, chronic
360 stress, undernutrition) as well as genetic influences not captured by the PGS, and future studies
361 will identify these factors and determine how they contribute to CAD risk.

362

363 An alternative possibility is that later AAM itself does in fact cause increased risk of CAD,
364 regardless of underlying source of variation. For this to be true, given our finding that later
365 genetically predicted AAM is associated with lower CAD risk, there would have to be strong
366 direct (pleiotropic) effects of common genetic variants on risk of CAD, with later genetically

367 predicted AAM strongly protective against CAD, such that the net effect is the lower risk of
368 CAD that we observed with later genetically predicted AAM. However, previous MR studies
369 have suggested that such pleiotropic effects of common genetic variants for AAM on risk of
370 CAD are small (10,31–33). Hence, this alternative possibility is not supported by existing
371 evidence, and the more likely explanation is that PGS-independent factors that cause later AAM
372 have direct deleterious effects on CAD risk factors and CAD.

373

374 Earlier AAM, whether attributable to common genetic variants or other sources of variation, was
375 consistently associated with greater cardiometabolic risk. Thus, it seems that earlier AAM itself
376 is intrinsically associated with risk for CAD and worsening CAD risk factors; indeed, some
377 Mendelian randomization studies suggest that earlier AAM is causative of these negative
378 outcomes (11,31). However, other Mendelian randomization studies have suggested that,
379 because many loci that affect AAM also affect BMI, the associations with increased risk of CAD
380 are mainly through effects on BMI, and AAM itself may have only a small direct influence
381 (10,33).

382

383 The U-shaped relationship of PGS-adjusted AAM with CAD was mirrored by the relationships
384 with HbA1c, triglycerides, HDL-C, and waist-hip ratio. This raises the possibility that
385 dysglycemia, dyslipidemia, and central adiposity contribute to the relationship between later
386 AAM and increased risk of CAD; further studies will be required to formally evaluate these
387 CAD risk factors as potential mediators of this relationship. As noted above, previous studies
388 evaluating associations of later AAM with these CAD risk factors have had conflicting results.

389 While differences between study cohorts may have accounted for some of the differing results,
390 our findings raise the additional possibility that the relationships between later AAM and these
391 outcomes may have been obscured by opposing effects of genetically predicted and PGS-
392 adjusted variation in AAM. Of note, the associations with waist-hip ratio differed from those
393 with BMI, suggesting that central adiposity, reflected by waist-hip ratio, is more relevant than
394 BMI for CAD, as has been suggested by prior studies (34,35).

395

396 Given the well-known effects of increased adiposity on CAD and CAD risk factors such as
397 dysglycemia and dyslipidemia, it is possible that associations of PGS-adjusted variation in AAM
398 with CAD, dysglycemia, and dyslipidemia are largely mediated by associations with BMI and
399 central adiposity; however, we were unable to test this possibility with UK Biobank data. The
400 relationship between AAM and BMI is complex because childhood BMI – not available in the
401 UK Biobank – affects both AAM and adult BMI, and AAM is itself also associated with adult
402 BMI. Thus, adjusting for adult BMI would introduce collider bias. Future work could focus on
403 disentangling these associations by using cohorts with measures of childhood BMI and/or
404 genetic tools such as clustering analyses to generate partitioned polygenic scores (36,37).

405

406 Our analyses in the Women's Genome Health Study (WGHS) largely validated our results from
407 the UK Biobank. Genetically predicted AAM demonstrated linear relationships with CAD and
408 CAD risk factors, and PGS-adjusted AAM demonstrated mostly non-linear relationships with
409 these outcomes, supporting the conclusions described earlier. However, the two cohorts also
410 demonstrated some differences, most notably in the association of PGS-adjusted AAM with the

411 risk of CAD and waist-hip ratio. In the UK Biobank, PGS-adjusted *later* AAM was associated
412 with an increased risk of CAD, but there was no association in the WGHS. For waist-hip ratio,
413 PGS-adjusted AAM demonstrated a clear U-shaped association in the UK Biobank but a reverse
414 J-shaped relationship in the WGHS. There are several potential reasons for this difference. First,
415 it is possible that the smaller sample size and lower power in the WGHS affected the ability to
416 find significant associations with PGS-adjusted AAM and risk of CAD and waist-hip ratio.
417 Second, environmental influences affecting AAM (which would contribute to PGS-adjusted
418 AAM) could differ between the two cohorts. The WGHS recruited women in the United States
419 of America born in 1950 or earlier, while the UK Biobank recruited women in the UK who were
420 born between 1932 and 1969. The different impact of global events such as World War II on the
421 two countries could contribute to differences in the PGS-independent factors (which includes
422 environmental factors) and, in turn, to different associations with risk of CAD. Third, the WGHS
423 excluded women with a history of CAD at the time of enrollment whereas the UK Biobank did
424 not, and this may also have led to differences in PGS-adjusted factors between the cohorts.
425 Fourth, the participants in the WGHS were health professionals while the UK Biobank drew
426 from the general UK population, and this may have led to further differences in PGS-adjusted
427 factors, such as higher socioeconomic status, greater knowledge of CAD and its risk factors,
428 healthier diets and lifestyles, and use of preventative interventions, as well as potentially less
429 variation in these factors. While the analyses also differed in the CAD measure used from each
430 cohort – prevalence of CAD was analyzed in the UK Biobank compared to incidence of CAD in
431 the WGHS – it is unlikely to account for the difference in results, as an analysis of incident CAD
432 in the Million Women Study in the UK also showed a U-shaped relationship between AAM and
433 CAD (1). Despite these differences in the results between the two cohorts, results from both

434 cohorts consistently demonstrated differences between the associations of *earlier* vs. *later* PGS-
435 adjusted AAM with these outcomes.

436

437 In 2021, Liang et al. used a PGS to represent genetically predicted AAM and examined
438 associations with all-cause mortality, also using data from the UK Biobank. Interestingly, they
439 found a U-shaped association with mortality, with both earlier and later genetically predicted
440 AAM associated with higher risk; this finding contrasts with the linear relationship we found
441 between genetically predicted AAM and CAD. This difference suggests that later genetically
442 predicted AAM increases the risk of causes of mortality other than CAD, and future studies of
443 genetically predicted AAM are needed to identify these causes.

444

445 Prior studies that have also dissected influences on human traits into genetic vs. environmental
446 influences have found differences in the magnitude of effect of genetics vs. environmental
447 influences on health outcomes (21,22). Interestingly, our results show not only different
448 magnitudes of association of genetically predicted and PGS-adjusted AAM with risk of CAD,
449 but also opposite directionality. This further underscores the value of separating the effects of
450 genetics vs. other influences while studying human traits as they can have starkly different
451 effects.

452

453 Sensitivity analyses using a GWAS that did not include the primary cohort, the UK Biobank,
454 produced similar results and suggested that these results were not biased by overfitting.

455 Additionally, sensitivity analyses excluding women with extreme values of AAM also produced
456 similar results, suggesting that results were not heavily influenced by outliers.

457

458 One limitation of this study is that while the PGS represents genetic influences on AAM, it does
459 not represent all genetic factors that influence AAM. Our analyses demonstrated that the PGS
460 explains 15.8% of the variation in the observed AAM, but prior studies suggest that 49-73% of
461 variation in AAM is inherited (18,19); hence, a large amount of the variation in AAM due to
462 genetic factors remains unexplained. Another limitation of this study is that the PGS represents
463 just one method of capturing the effects of common genetic variants that affect AAM. There may
464 be several pathways causing later AAM represented within these common genetic variants, and
465 using a single PGS to represent all those effects may obscure relationships with each individual
466 pathway. Future studies may identify these different pathways by methods such as clustering
467 analyses (36,37), which would then allow an estimation of multiple polygenic scores, each
468 representing a different pathway, to study their associations with risk of CAD and CAD risk
469 factors.

470

471 Distinguishing between sources of variation in AAM has provided a novel lens through which to
472 study associations of AAM with CAD and has allowed us to uncover differences in the
473 associations of genetically predicted vs. PGS-adjusted AAM with CAD and CAD risk factors.
474 Because later puberty in women, but not men, has been associated with an increased risk of
475 CAD, studying these differences further may provide unique insights into mechanisms that affect
476 CAD risk specifically in women.

ACKNOWLEDGEMENTS

The authors thank Evan Schafer and Jia Zhu for their support with statistical analyses. This research has been conducted using data from UK Biobank, a major biomedical database: www.ukbiobank.ac.uk

SOURCES OF FUNDING

A.S. was supported by National Institutes of Health (NIH) grant T32DK007699. The WGHS and its parent cohort, the Women's Health Study (WHS), have been supported by the National Heart, Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913), with support and funding for genotyping provided by Amgen. Some cardiovascular endpoints in the WHS were funded by HL099355.

488 **REFERENCES**


489 1. Canoy D, Beral V, Balkwill A, Wright FL, Kroll ME, Reeves GK, et al. Age at menarche and risks of
490 coronary heart and other vascular diseases in a large UK cohort. Circulation [Internet]. 2015
491 [cited 2021 Dec 11];131(3):237–44. Available from: https://pubmed.ncbi.nlm.nih.gov/25512444/

492 2. Zhu J, Chan YM. Adult Consequences of Self-Limited Delayed Puberty. Pediatrics [Internet]. 2017
493 Jun 1 [cited 2021 Aug 29];139(6). Available from: www.aappublications.org/news

494 3. Day FR, Elks CE, Murray A, Ong KK, Perry JRB. Puberty timing associated with diabetes,
495 cardiovascular disease and also diverse health outcomes in men and women: the UK Biobank
496 study. Sci Rep [Internet]. 2015 Jun 18 [cited 2021 Dec 11];5. Available from:
497 https://pubmed.ncbi.nlm.nih.gov/26084728/

498 4. Lee JJ, Cook-Wiens G, Johnson BD, Braunstein GD, Berga SL, Stanczyk FZ, et al. Age at Menarche
499 and Risk of Cardiovascular Disease Outcomes: Findings From the National Heart Lung and Blood
500 Institute-Sponsored Women's Ischemia Syndrome Evaluation. J Am Heart Assoc [Internet]. 2019
501 Jun 18 [cited 2024 Jun 10];8(12). Available from:
502 https://www.ahajournals.org/doi/abs/10.1161/JAHA.119.012406

503 5. Santos MP, Li Y, Bazzano LA, He J, Rexrode KM, Ley SH. Age at menarche, type 2 diabetes and
504 cardiovascular disease complications in US women aged under 65 years: NHANES 1999-2018.
505 BMJ Nutr Prev Health [Internet]. 2023 Dec 1 [cited 2024 Apr 10];6(2):293–300. Available from:
506 https://pubmed.ncbi.nlm.nih.gov/38264363/

507 6. Janghorbani M, Mansourian M, Hosseini E. Systematic review and meta-analysis of age at
508 menarche and risk of type 2 diabetes. Acta Diabetol [Internet]. 2014 [cited 2024 Apr
509 10];51(4):519–28. Available from: https://pubmed.ncbi.nlm.nih.gov/24671509/

510 7. Stöckl D, Meisinger C, Peters A, Thorand B, Huth C, Heier M, et al. Age at menarche and its
511 association with the metabolic syndrome and its components: results from the KORA F4 study.
512 PLoS One [Internet]. 2011 Oct 18 [cited 2021 Dec 11];6(10). Available from:
513 https://pubmed.ncbi.nlm.nih.gov/22028807/

514 8. Liu D, Qin P, Liu Y, Sun X, Li H, Wu X, et al. Association of age at menarche with hypertension in
515 rural Chinese women. J Hypertens. 2021 Mar 1;39(3):476–83.

516 9. Kheradmand M, Hamzehgardeshi Z, Shahhosseini Z, Mirjalili R, Moosazadeh M. The association
517 between early menarche and higher-risk cardiometabolic profile: a dose-response analysis of the
518 Tabari cohort at enrollment phase. Front Cardiovasc Med [Internet]. 2023 [cited 2024 Apr 10];10.
519 Available from: https://pubmed.ncbi.nlm.nih.gov/37719973/

520 10. Cao M, Cui B. Negative Effects of Age at Menarche on Risk of Cardiometabolic Diseases in
521 Adulthood: A Mendelian Randomization Study. J Clin Endocrinol Metab [Internet]. 2020 Jan 23
522 [cited 2022 Feb 23];105(2). Available from: https://pubmed.ncbi.nlm.nih.gov/31614369/

523 11. Gill D, Brewer CF, Del Greco M F, Sivakumaran P, Bowden J, Sheehan NA, et al. Age at menarche
524 and adult body mass index: a Mendelian randomization study. International Journal of Obesity

525 2018 42:9 [Internet]. 2018 Feb 26 [cited 2023 Feb 12];42(9):1574–81. Available from:
526 https://www-nature-com.ezp-prod1.hul.harvard.edu/articles/s41366-018-0048-7

527 12. Prentice P, Viner RM. Pubertal timing and adult obesity and cardiometabolic risk in women and
528 men: a systematic review and meta-analysis. Int J Obes (Lond) [Internet]. 2013 Aug [cited 2021
529 Dec 11];37(8):1036–43. Available from: https://pubmed.ncbi.nlm.nih.gov/23164700/

530 13. Yang L, Li L, Millwood IY, Lewington S, Guo Y, Sherliker P, et al. Adiposity in relation to age at
531 menarche and other reproductive factors among 300 000 Chinese women: findings from China
532 Kadoorie Biobank study. Int J Epidemiol [Internet]. 2017 Jan 1 [cited 2022 Mar 17];46(2):502–12.
533 Available from: https://pubmed.ncbi.nlm.nih.gov/27524817/

534 14. Chen L, Zhang L, Chen Z, Wang X, Zheng C, Kang Y, et al. Age at menarche and risk of
535 hypertension in Chinese adult women: Results from a large representative nationwide
536 population. J Clin Hypertens (Greenwich) [Internet]. 2021 Aug 1 [cited 2023 Dec 7];23(8):1615–
537 21. Available from: https://pubmed.ncbi.nlm.nih.gov/34255920/

538 15. Liu D, Zhao Y, Liu Y, Sun X, Li H, Yin Z, et al. Adiposity and insulin resistance as mediators between
539 age at menarche and type 2 diabetes mellitus. Menopause [Internet]. 2020 May 1 [cited 2022
540 Apr 1];27(5):579–85. Available from: https://pubmed-ncbi-nlm-nih-gov.ezp-
541 prod1.hul.harvard.edu/32068689/

542 16. Elks CE, Ong KK, Scott RA, Van Der Schouw YT, Brand JS, Wark PA, et al. Age at menarche and
543 type 2 diabetes risk: the EPIC-InterAct study. Diabetes Care [Internet]. 2013 Nov [cited 2022 Apr
544 1];36(11):3526–34. Available from: https://pubmed-ncbi-nlm-nih-gov.ezp-
545 prod1.hul.harvard.edu/24159179/

546 17. Schlomer GL, Marceau K. Father absence, age at menarche, and genetic confounding: A
547 replication and extension using a polygenic score. Dev Psychopathol [Internet]. 2022 Feb 27
548 [cited 2024 May 13];34(1):355–66. Available from: https://pubmed.ncbi.nlm.nih.gov/33107423/

549 18. Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for age at
550 menarche: Analyses from the breakthrough generations study. Paediatr Perinat Epidemiol. 2011
551 May;25(3):306–11.

552 19. Towne B, Czerwinski SA, Demerath EW, Blangero J, Roche AF, Siervogel RM. Heritability of age at
553 menarche in girls from the Fels Longitudinal Study. Am J Phys Anthropol. 2005 Sep;128(1):210–9.

554 20. Day FR, Thompson DJ, Helgason H, Chasman DI, Finucane H, Sulem P, et al. Genomic analyses
555 identify hundreds of variants associated with age at menarche and support a role for puberty
556 timing in cancer risk. Nat Genet [Internet]. 2017 Jun 1 [cited 2022 Jul 26];49(6):834. Available
557 from: /pmc/articles/PMC5841952/

558 21. Ojalehto E, Zhan Y, Jylhävä J, Reynolds CA, Dahl Aslan AK, Karlsson IK. Genetically and
559 environmentally predicted obesity in relation to cardiovascular disease: a nationwide cohort
560 study. EClinicalMedicine [Internet]. 2023 Apr 1 [cited 2024 Jun 9];58. Available from:
561 http://www.thelancet.com/article/S2589537023001207/fulltext

562 22. Hawkes G, Yengo L, Vedantam S, Marouli E, Beaumont RN, Tyrrell J, et al. Identification and
563 analysis of individuals who deviate from their genetically-predicted phenotype. PLoS Genet
564 [Internet]. 2023 Sep 21 [cited 2024 Jun 9];19(9). Available from:
565 https://pubmed.ncbi.nlm.nih.gov/37733769/

566 23. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access
567 resource for identifying the causes of a wide range of complex diseases of middle and old age.
568 PLoS Med [Internet]. 2015 Mar 1 [cited 2022 Mar 10];12(3). Available from: https://pubmed-
569 ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/25826379/

570 24. Zhu J, Pujol-Gualdo N, Wittemans LBL, Lindgren CM, Laisk T, Hirschhorn JN, et al. Evidence From
571 Men for Ovary-independent Effects of Genetic Risk Factors for Polycystic Ovary Syndrome. J Clin
572 Endocrinol Metab [Internet]. 2022 Mar 24 [cited 2022 Jul 27];107(4):e1577–87. Available from:
573 https://academic-oup-com.ezp-prod1.hul.harvard.edu/jcem/article/107/4/e1577/6432124

574 25. UK Biobank age at menarche data collection:
575 https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=2714.

576 26. Ridker PM, Chasman DI, Zee RYL, Parker A, Rose L, Cook NR, et al. Rationale, design, and
577 methodology of the Women's Genome Health Study: a genome-wide association study of more
578 than 25,000 initially healthy american women. Clin Chem [Internet]. 2008 [cited 2023 Nov
579 2];54(2):249–55. Available from: https://pubmed.ncbi.nlm.nih.gov/18070814/

580 27. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and
581 continuous shrinkage priors. Nat Commun [Internet]. 2019 Dec 1 [cited 2022 Dec 7];10(1).
582 Available from: https://pubmed.ncbi.nlm.nih.gov/30992449/

583 28. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience
584 [Internet]. 2019 Jul 1 [cited 2022 Dec 7];8(7). Available from:
585 https://pubmed.ncbi.nlm.nih.gov/31307061/

586 29. Sonawalla A, Chasman D, Chan YM. Hold for placement of supplemental materials.

587 30. Perry JRB, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, et al. Parent-of-origin specific allelic
588 associations among 106 genomic loci for age at menarche. Nature [Internet]. 2014 Oct 10 [cited
589 2024 Jun 17];514(7520):97. Available from: /pmc/articles/PMC4185210/

590 31. Zheng J, Chen K, Huang T, Shao C, Li P, Wang J, et al. Genetically Determined Lifestyle and
591 Cardiometabolic Risk Factors Mediate the Association of Genetically Predicted Age at Menarche
592 With Genetic Predisposition to Myocardial Infarction: A Two-Step, Two-Sample Mendelian
593 Randomization Study. Front Cardiovasc Med [Internet]. 2022 Apr 25 [cited 2023 Apr 20];9.
594 Available from: /pmc/articles/PMC9081496/

595 32. Ardissino M, Slob EAW, Carter P, Rogne T, Girling J, Burgess S, et al. Sex-Specific Reproductive
596 Factors Augment Cardiovascular Disease Risk in Women: A Mendelian Randomization Study.
597 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
598 [Internet]. 2023 Mar 7 [cited 2024 Nov 17];12(5):e027933. Available from:
599 https://pmc.ncbi.nlm.nih.gov/articles/PMC10111460/

600 33. Bell JA, Carslake D, Wade KH, Richmond RC, Langdon RJ, Vincent EE, et al. Influence of puberty
601 timing on adiposity and cardiometabolic traits: A Mendelian randomisation study. PLoS Med
602 [Internet]. 2018 Aug 1 [cited 2022 Feb 23];15(8). Available from:
603 https://pubmed.ncbi.nlm.nih.gov/30153260/

604 34. Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and
605 waist:hip ratio as predictors of cardiovascular risk--a review of the literature. Eur J Clin Nutr
606 [Internet]. 2010 Jan [cited 2024 May 30];64(1):16–22. Available from: www.nature.com/ejcn

607 35. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. Normal-
608 Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern Med
609 [Internet]. 2015 Dec 1 [cited 2024 Jun 9];163(11):827–35. Available from:
610 https://pubmed.ncbi.nlm.nih.gov/26551006/

611 36. Chasman DI, Giulianini F, Demler O V., Udler MS. Pleiotropy-Based Decomposition of Genetic Risk
612 Scores: Association and Interaction Analysis for Type 2 Diabetes and CAD. Am J Hum Genet
613 [Internet]. 2020 May 7 [cited 2024 Jun 9];106(5):646–58. Available from:
614 https://pubmed.ncbi.nlm.nih.gov/32302534/

615 37. Udler MS, Kim J, von Grotthuss M, Bonàs-Guarch S, Cole JB, Chiou J, et al. Type 2 diabetes genetic
616 loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft
617 clustering analysis. PLoS Med [Internet]. 2018 Sep 1 [cited 2024 Jun 9];15(9). Available from:
618 https://pubmed.ncbi.nlm.nih.gov/30240442/

619

620

621 **TABLES**

| **Coronary artery disease** | | | | | |
|---|---|---|---|---|---|
| | **Change per year increase in AAM** | | | | |
| | **Values earlier than the mean** | | **Values later than the mean** | | ***p* for difference between slopes** |
| | Odds ratio (95% CI) | *p* | Odds ratio (95% CI) | *p* | |
| Genetically predicted AAM | 0.91 (0.83 to 0.99) | $3x10^{-2}$ | 0.92 (0.84 to 1) | 0.063 | 0.87 |
| PGS-adjusted AAM | 0.92 (0.88 to 0.95) | $3x10^{-6}$ | 1.11 (1.08 to 1.15) | $2x10^{-9}$ | $7x10^{-10}$ |
| **Coronary artery disease risk factors** | | | | | |
| | **Change per year increase in AAM** | | | | |
| | **Values earlier than the mean** | | **Values later than the mean** | | ***p* for difference between slopes** |
| | Slope (95% CI) | *p* | Slope (95% CI) | *p* | |
| **Hemoglobin A1c (%)** | | | | | |
| Genetically predicted AAM | -0.034 (-0.041 to -0.027) | $<2x10^{-16}$ | -0.01 (-0.02 to -0.006) | $3x10^{-3}$ | $6x10^{-5}$ |
| PGS-adjusted AAM | -0.022 (-0.025 to -0.019) | $<2x10^{-16}$ | 0.007 (0.004 to 0.01) | $1.3x10^{-6}$ | $<2x10^{-16}$ |
| **Triglycerides (mg/dL)** | | | | | |
| Genetically predicted AAM | -2.82 (-3.84 to -1.79) | $7x10^{-8}$ | -2.63 (-3.62 to -1.64) | $2x10^{-7}$ | 0.83 |
| PGS-adjusted AAM | -4.25 (-4.7 to -3.8) | $<2x10^{-16}$ | 1.2 (0.78 to 1.62) | $2x10^{-8}$ | $<2x10^{-16}$ |
| **High-density lipoprotein (HDL) cholesterol (mg/dL)** | | | | | |
| Genetically predicted AAM | 0.90 (0.69-1.11) | $<2x10^{-16}$ | 0.74 (0.54-0.95) | $8x10^{-13}$ | 0.38 |

| | | | | | |
|---|---|---|---|---|---|
| PGS-adjusted AAM | 0.85 (0.76-0.95) | $<2x10^{-16}$ | -0.28 (-0.37 to -0.20) | $2x10^{-10}$ | $<2x10^{-16}$ |
| **Low-density lipoprotein (LDL) cholesterol (mg/dL)** | | | | | |
| | Adjusted for LDL-lowering medications | | | | |
| Genetically predicted AAM | 0.27 (-0.15 to 0.69) | $2x10^{-1}$ | -0.53 (-0.93 to -0.12) | $1x10^{-2}$ | 0.026 |
| PGS-adjusted AAM | -0.46 (-0.65 to -0.28) | $1x10^{-6}$ | 0.067 (-0.11 to 0.24) | 0.45 | $7x10^{-4}$ |
| | Including only those not taking LDL-lowering medications (n = 177,542) | | | | |
| Genetically predicted AAM | 0.14 (-0.31 to 0.59) | 0.054 | -0.59 (-1.02 to -0.16) | $8x10^{-3}$ | 0.059 |
| PGS-adjusted AAM | -0.53 (-0.72 to -0.33) | $3x10^{-7}$ | 0.0065 (-0.18 to 0.19) | 0.9 | $2x10^{-3}$ |
| **Systolic blood pressure (mmHg)** | | | | | |
| Genetically predicted AAM | -0.73 (-0.99 to -0.47) | $4x10^{-8}$ | -0.71 (-0.96 to -0.45) | $5x10^{-8}$ | 0.91 |
| PGS-adjusted AAM | -0.69 (-0.81 to -0.58) | $<2x10^{-16}$ | -0.21 (-0.31 to -0.10) | $2x10^{-4}$ | $5x10^{-7}$ |
| **Diastolic blood pressure (mmHg)** | | | | | |
| Genetically predicted AAM | -0.49 (-0.63 to -0.34) | $5x10^{-11}$ | -0.49 (-0.63 to -0.35) | $9 x10^{-12}$ | 0.98 |
| PGS-adjusted AAM | -0.52 (-0.59 to -0.46) | $<2x10^{-16}$ | -0.14 (-0.20 to -0.08) | $5 x10^{-6}$ | $2x10^{-12}$ |
| **Body-mass index (kg/m$^2$)** | | | | | |
| Genetically predicted AAM | -0.98 (-1.05 to -0.91) | $<2x10^{-16}$ | -0.77 (-0.84 to -0.70) | $<2 x10^{-16}$ | $4x10^{-4}$ |
| PGS-adjusted AAM | -0.80 (-0.83 to -0.77) | $<2x10^{-16}$ | -0.079 (-0.11 to -0.051) | $4 x10^{-8}$ | $<2x10^{-16}$ |
| **Waist-hip ratio** | | | | | |
| Genetically predicted AAM | -0.0038 (-0.0047 to -0.0029) | $1.1x10^{-15}$ | -0.0029 (-0.0038 to -0.0020) | $2x10^{-10}$ | 0.28 |
| PGS-adjusted AAM | -0.0046 (-0.0050 to -0.0042) | $<2x10^{-16}$ | 0.0016 (0.0012 to 0.0020) | $<2x10^{-16}$ | $<2x10^{-16}$ |

622

623 **Table 1:** Associations of genetically predicted and PGS-adjusted AAM with coronary artery

624 disease and its risk factors.

625 AAM: age at menarche; PGS: polygenic score

626 **FIGURES**




627

628 **Figure 1:** Relationships of different sources of variation in age at menarche (AAM) with
629 coronary artery disease (CAD) and CAD risk factors. Variation in AAM was dissected into
630 variation associated with common genetic variants (as estimated by a polygenic score for AAM)
631 and variation independent of the polygenic score, then associations of these sources of variation
632 with CAD and CAD risk factors were studied. When associated with common genetic variants,
633 later AAM was associated with a lower risk of CAD and favorable changes in CAD risk factors
634 (blue arrows). However, when occurring independently of the polygenic score, later AAM was
635 associated with higher risk of CAD and unfavorable changes in CAD risk factors (red arrows).
636 The "other factors" causing later AAM independent of the PGS have yet to be identified and
637 could potentially include chronic illness, underweight, and rare genetic variants.




**Figure 2: Associations of different sources of variation in age at menarche (AAM) with odds of coronary artery disease (CAD) in the UK Biobank.** For each individual in the cohort, variation in AAM was dissected into variation attributable to common genetic variants as estimated by a polygenic score (PGS) for AAM (represented by "genetically predicted AAM") and variation attributable to sources other than common genetic variants (represented by "PGS-adjusted AAM"), then associations with risk of CAD were studied. Genetically predicted AAM showed a linear association with risk of CAD, whereas PGS-adjusted AAM showed a U-shaped

association. The different associations of genetically predicted AAM and PGS-adjusted AAM with risk of CAD suggest that it's not later AAM itself that causes increased risk of CAD, but that factors other than the PGS can cause both later AAM and increased risk of CAD.. To achieve bin sizes of ≥1000 individuals, the first and last bins for each variable represent the group of individuals with AAM ≤ or ≥ the value listed on the x-axis, respectively. Dots represent estimates; bars represent standard errors.




**Figure 3: Associations of genetically predicted and PGS-adjusted AAM with risk factors for CAD in the UK Biobank.** We observed linear (or roughly linear) relationships between genetically predicted AAM and most CAD risk factors. In contrast, for PGS-adjusted AAM we observed mostly non-linear relationships with CAD risk factors. The U-shaped relationship of PGS-adjusted AAM with CAD was mirrored by the relationships with HbA1c, triglycerides, HDL-C, and waist-hip ratio. This raises the possibility that dysglycemia, dyslipidemia and central adiposity may mediate the relationship between later AAM and increased risk of CAD. For LDL-C, n = 177,542 after excluding those taking LDL-C lowering medications. Dots represent estimates, bars represent standard errors.

663 AAM: age at menarche; BMI: body mass index; CAD: coronary artery disease; HDL-C: high-
664 density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; PGS: polygenic
665 score




**Figure 4: Associations of genetically predicted and PGS-adjusted AAM with risk factors for CAD in the WGHS.** genetically predicted AAM showed linear or roughly linear associations with most CAD risk factors and PGS-adjusted AAM showed mostly non-linear associations with most CAD risk factors. Similar to results in the UK Biobank, hemoglobin A1c, triglycerides and HDL-C showed U-shaped associations with PGS-adjusted AAM which support conclusions from the primary analyses that dysglycemia, dyslipidemia and central adiposity may mediate the relationship between later AAM and increased risk of CAD. For LDL-C, n = 22,495 after excluding those taking cholesterol-lowering medications. Dots represent estimates, bars represent standard errors.

676 AAM: age at menarche; BMI: body mass index; CAD: coronary artery disease; HDL-C: high
677 density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; PGS: polygenic
678 score; WGHS: Women's Genome Health Study.




| | 10 | 10.5 | 11 | 11.5 | 12 | 12.5 | 13 | 13.5 | 14 | 14.5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Genetically predicted AAM, *n* | | | 2,533 | 4,143 | 5,878 | 5,462 | 3,367 | 1,885 | | |
| PGS-adjusted AAM, *n* | 1,275 | 1,557 | 2,445 | 3,527 | 4,070 | 3,826 | 1,691 | 2,779 | 938 | 1,160 |

**Figure 5: Associations of genetically predicted and PGS-adjusted AAM with hazard ratio for risk of CAD in the WGHS.** Genetically predicted AAM demonstrated a negative linear association with risk of CAD, similar to the results in the UKBB. PGS-adjusted AAM demonstrated a reverse-J shaped relationship, slightly different from the U-shaped relationship seen in the UK Biobank. Analyses in the WGHS largely validated the results from the UK

685 Biobank. The different associations of later PGS-adjusted AAM with risk of CAD may have
686 been due to differences in environmental factors between the two study cohorts.

687 AAM: age at menarche; ΔAAM: change in AAM; CAD: coronary artery disease; PGS:
688 polygenic score. Dots represent estimates, bars represent standard errors.